Tutofusin OPS

Description
Tutofusin OPS covers basic water and electrolyte requirements in the preoperative,
intraoperative, and postoperative phase, stabilizes the water-electrolyte balance
thereby ensuring continued homeostasis, generally saves additional, complicated
correctional therapy, and with its 5% sorbitol component enables a reduction of acute
postoperative protein catabolism.
Composition
1000 mL infusion solution contain :
Sodium chloride
Potassium chloride
Calcium chloride
Magnesium chloride
Sodium acetate
Sorbitol
in water for injection

3.623 g
1.342 g
0.294 g
0.610 g
5.171 g
50.0 g

Yielding :
Na+
K+
Ca++
Mg++
ClAcetate-

mEq/l
100
18
4
6
90
38

mmol/l
100
18
2
3
90
38

mg/l
2299
704
80
73
3191
2243

1000 mL contain 850 kJ ( approx. 200 kcal )

Osmolarity : approx. 500 mOsm/L
Indications
To cover water and electrolyte requirements in the preoperative, intraoperative, and
postoperative phase; to partially cover carbohydrate requirements; isotonic
dehydration; loss of extracellular fluids; as a vehicle solution.
Contraindications
Tutofusin OPS is contraindicated in patients with renal insufficiency, fructose and
sorbitol intolerance, fructose-1-6-diphosphatase deficiency, methyl alcohol poisoning
Warning and Precautions
- Ensure adequate renal function
- Use with caution in patients with hyperkalemia and hyperhydration.
- Not suitable for shock therapy
- Solutions containing sodium ions should be used with great care, if at all, in patients
with congestive heart failure, severe renal insufficiency and in clinical states in
which there exist edema with sodium retention.

- The intravenous administration of this solution can cause fluid and/or solute
overloading resulting in dilution of serum electrolyte concentrations, overhydration,
congested states or pulmonary edema. The risk of dilutional states is inversely
propotional to the electrolyte concentrations of the administered parenteral
solutions. The states with peripheral and pulmonary edema is directly proportional
to the electrolyte concentrations of such solutions.
- Use only clear solutions in condition of intact containers
Adverse Reactions
If used as directed, adverse reactions and side effects should not occur. Reaction
which may occur because of the solution or the technique of administration include
febrile response, infection at the site of injection, venous thrombosis or phlebitis
extending from the site of injection, extravasation and hypervolaemia. If an adverse
reaction occurs, discontinue infusion.
Dosage and Administration
For intravenous infusion.
Dosage according to individual requirements, unless otherwise prescribed : 30 ml/kg
BW/day (equivalent to 1.5 g sorbitol/kgBW/day).
Presentation
Infusion solution in bottles containing 500 mL.
Store below 25 C.